Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Synopsys, Inc. — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Synopsys, Inc. trades at $474.06 (market cap $94.77B). The key difference: Synopsys, Inc. is far larger — about 3.1× GE HealthCare Technologies Inc. Common Stock's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| GEHC | SNPS | |
|---|---|---|
Market Cap | $31.07B | $94.77B |
Volume | 3,443,020 | 2,520,237 |
Sector | Health | Technology |
52-Week High | $88.16 | $534.56 |
52-Week Low | $59.48 | $367.70 |
Enterprise Value | $39.53B | $102.00B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 72 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Synopsys (SNPS) trades at $479.93, down 4.49% today but remains in a strong technical uptrend with bullish moving averages. The company demonstrates robust fundamentals with Q2 2026 EPS of $3.91 beating expectations by 6.5% and maintains strong profitability with 72.38% gross margins. Recent investor day announcements highlighted transformative AI partnerships with OpenAI and Amazon, driving positive sentiment and analyst upgrades.
Outlook remains positive with 93% analyst buy ratings and $575.93 consensus target offering 20% upside. Key opportunities include AI-driven chip design growth and Ansys integration synergies, while risks involve execution challenges and premium valuation at 86.3 P/E. The stock presents a compelling growth story but requires monitoring of integration progress and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
